Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Frazier Life Sciences is a prominent biotech investment firm founded in 2015 and headquartered in Palo Alto, California. With a robust capital management of over $5.3 billion, the firm specializes in partnering with and building companies that develop novel therapeutics. Frazier Life Sciences has established a reputation for its strategic focus on early-stage private biopharmaceutical companies, particularly in North America and Europe. The firm’s leadership is committed to advancing innovative solutions in the biopharmaceutical sector, emphasizing company creation and Series A investments. Since its inception, Frazier Life Sciences has successfully created over 25 companies and has been involved in more than 50 IPOs and mergers and acquisitions (M&As), representing a cumulative transaction value exceeding $75 billion. This impressive track record underscores the firm’s significant impact on the biotech landscape and its ability to identify and nurture promising ventures.
Frazier Life Sciences maintains a clear investment focus on early-stage private biopharmaceutical companies, particularly those located in the U.S. and Europe. The firm’s investment strategy encompasses both venture capital and public equity approaches, aimed at advancing novel therapeutics that address unmet medical needs. Frazier Life Sciences places a strong emphasis on company creation and Series A investments, targeting product-focused companies capable of generating meaningful clinical data or successfully commercializing therapeutics. The firm actively seeks out innovative startups that are developing groundbreaking solutions in the biotech and healthcare sectors, particularly those that demonstrate potential for significant clinical advancements. By leveraging its extensive resources and industry expertise, Frazier Life Sciences aims to foster the growth of companies that can make a substantial impact on patient care and treatment outcomes.
Frazier Life Sciences boasts a diverse portfolio of over 25 companies, showcasing its commitment to fostering innovation in the biopharmaceutical sector. The firm has played a pivotal role in the success of notable portfolio companies such as Krystal Biotech, which specializes in gene therapies for rare genetic diseases, and Alpine Immune Sciences, which was acquired by Vertex for an impressive $4.9 billion. Additionally, Radionetics Oncology, a company focused on radiopharmaceuticals for oncology, exemplifies the firm’s investment in cutting-edge therapeutic solutions. Frazier Life Sciences has also been actively involved in more than 50 IPOs and M&As, collectively representing over $75 billion in transaction value. This extensive experience in the biotech market positions Frazier Life Sciences as a key player in driving innovation and facilitating successful exits for its portfolio companies.
To pitch Frazier Life Sciences, founders should visit their website at frazierls.com. The firm is open to pitches from innovative biotech companies, and it is advisable to ensure that the pitch aligns with their focus on early-stage investments in the biopharmaceutical sector.
Frazier Life Sciences primarily invests in early-stage companies, focusing on Seed and Series A rounds. The firm is particularly interested in partnering with startups that are developing novel therapeutics in the biopharmaceutical sector.
Founders can pitch Frazier Life Sciences by visiting their website at frazierls.com. The firm welcomes pitches from innovative biotech companies that align with their investment focus.
The firm specializes in the biotech and healthcare sectors, with a strong emphasis on early-stage private biopharmaceutical companies. They seek companies that are developing novel therapeutics and have the potential for significant clinical impact.
While specific check sizes are not disclosed, Frazier Life Sciences focuses on Seed and Series A investments, which typically range from several million to tens of millions of dollars, depending on the company's stage and potential.
Frazier Life Sciences primarily invests in North America and Europe, targeting innovative biotech companies that are developing groundbreaking therapeutics in these regions.
Founders interested in applying for investment should submit their pitch through the firm’s website. They should ensure that their proposal aligns with Frazier Life Sciences' focus on early-stage biopharmaceutical companies.
Frazier Life Sciences offers strategic guidance and resources to its portfolio companies, leveraging its extensive industry expertise to support their growth and development in the competitive biotech landscape.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.